Drug intelligence / Profile preview

MV377

Development stage: Preclinical
Lead developer: MimiVax
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

MV377 is a preclinical-stage camelid single-domain antibody (sdAb), also known as a nanobody, developed by MimiVax. It is designed to target survivin (BIRC5), a member of the inhibitor of apoptosis (IAP) protein family that is highly expressed in many cancers but absent in most normal adult tissues. By binding to survivin, MV377 aims to inhibit its anti-apoptotic and mitotic functions, thereby promoting cancer cell death and inhibiting tumor growth.

Targets

BIRC5 (Survivin)

Beyond the preview

Go deeper on MV377.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MV377.

Explore the full profile